Form 8-K · Item 4.01 · Auditor change
Autolus Therapeutics plc: auditor change, Ernst & Young LLP (UK) to Ernst & Young LLP (US)
Autolus Therapeutics plc reported in a Form 8-K filed April 16, 2026, that on April 14, 2026, Ernst & Young LLP (UK) was dismissed as its certifying accountant, and Ernst & Young LLP (US) was engaged. The filing reports no disagreements with the former accountant.
In the filing's words
On April 14, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Autolus Therapeutics plc (the “Company”) dismissed Ernst & Young LLP (UK) (“EY UK”) as the Company’s independent registered public accounting firm.
there were no “disagreements” within the meaning of Item 304(a)(1)(iv) of Regulation S-K promulgated under the Securities Exchange Act (“Regulation S-K”) with EY UK on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures
On April 14, 2026, the Audit Committee approved the engagement of Ernst & Young LLP (US) (“EY US”) as its new independent registered public accounting firm.
Verbatim from sec.gov, Item 4.01 (Changes in Registrant's Certifying Accountant). We quote the filing; we do not characterize it.
| Company | Autolus Therapeutics plc |
|---|---|
| Ticker | AUTL |
| Form and item | 8-K, Item 4.01 |
| Filed with the SEC | April 16, 2026 |
| What the filing states | dismissed, engaged |
| Former accountant | Ernst & Young LLP (UK) |
| New accountant | Ernst & Young LLP (US) |
| Date of the change | April 14, 2026 |
| Disagreements | none reported |
| Auditor's letter | Exhibit 16 on sec.gov |
| Accession number | 0001730463-26-000049 |
| SEC CIK | 0001730463 |
Autolus Therapeutics plc reported under Form 8-K Item 4.01 (Changes in Registrant's Certifying Accountant), filed April 16, 2026. The filing's own words are quoted above.
Sources
More: all auditor changes · Something wrong? Send a correction with the primary source.